Harry P. Erba
Expertise in
23
conditions

Dr. Harry P. Erba

Oncology | Hematology
2400 Pratt St, 
Durham, NC 
On Staff At
Offers Telehealth
37 Years of Experience
Expertise in
23
conditions
2400 Pratt St, 
Durham, NC 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

I entered medical school for the sole purpose of learning more about human diseases, so that I could focus my laboratory efforts on improving the human condition. However, I was surprised to find myself drawn to clinical care. I care for people afflicted by acute leukemia, myelodysplastic syndromes, and myeloproliferative neoplasms. In this role, I have had the privilege of treating people facing life-threatening illnesses. I strive to gain the trust of each of my patients, so that I can help them make difficult treatment decisions. I engage in clinical research, evaluating novel agents that directly target the cancer cell to improve the degree of success in treating this illness. My patients benefit from my understanding of the newest available treatments, and also have access to promising investigational agents, when appropriate. In my faculty position at Duke University, I enjoy educating current oncologists as well as the next generation of physicians.

Dr. Erba is highly rated in 23 conditions, according to our data. His top areas of expertise are Acute Myeloid Leukemia (AML), Leukemia, Myelodysplastic Syndrome (MDS), Bone Marrow Aspiration, and Bone Marrow Transplant.

His clinical research consists of co-authoring 137 peer reviewed articles and participating in 17 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution
Stanford University School Of Medicine (California), 1988
Specialties
Oncology
Hematology
Licenses
Internal Medicine in MI
Board Certifications
American Board Of Internal Med, Hematology
Fellowships
Hematology-Oncology, Harvard Medical School, Brigham & Women's Hospital (Massachusetts)
Hospital Affiliations
Duke University Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Ambetter
  • EPO
  • HMO
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
FirstCarolinaCare
  • HMO
  • MEDICARE MAPD
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
MVP Health
  • EPO
  • PPO
Piedmont
  • HMO
  • POS
Sentara Healthcare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE ASSISTANCE PROGRAM
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 12 Less Insurance Carriers -

Locations

Duke Blood Cancer Center
2400 Pratt St, Durham, NC 27705
Other Locations
Duke Cancer Center
20 Duke Medicine Cir, Durham, NC 27710
Duke Hematologic Malignancies Clinic
2400 Pratt St, Durham, NC 27705

Additional Areas of Focus

Dr. Erba has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Leukemia

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

17 Clinical Trials

A Phase Ib, Multi-arm, Open-label, Study of HDM201 in Combination With MBG453 or Venetoclax in Adult Subjects With Acute Myeloid Leukemia (AML) or High-risk Myelodysplastic Syndrome (MDS)
A Phase Ib, Multi-arm, Open-label, Study of HDM201 in Combination With MBG453 or Venetoclax in Adult Subjects With Acute Myeloid Leukemia (AML) or High-risk Myelodysplastic Syndrome (MDS)
Enrollment Status: Terminated
Publish Date: October 10, 2025
Intervention Type: Biological, Drug
Study Drugs: HDM201, MBG453, Venetoclax
Study Phase: Phase 1
A Randomized Phase II/III Study of Conventional Chemotherapy +/- Uproleselan (GMI-1271) in Older Adults With Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy
A Randomized Phase II/III Study of Conventional Chemotherapy +/- Uproleselan (GMI-1271) in Older Adults With Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: October 09, 2025
Intervention Type: Drug, Procedure
Study Drugs: Cytarabine, Daunorubicin, Uproleselan
Study Phase: Phase 2/Phase 3
A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia in Adults
A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia in Adults
Enrollment Status: Active_not_recruiting
Publish Date: September 26, 2025
Intervention Type: Drug, Procedure, Biological
Study Drugs: Blinatumomab, Cyclophosphamide, Cytarabine, Daunorubicin, Daunorubicin Hydrochloride, Dexamethasone, Etoposide, Mercaptopurine, Methotrexate, Pegaspargase, Prednisone, Rituximab, Vincristine, Vincristine Sulfate
Study Phase: Phase 3
A Phase II Study of Inotuzumab Ozogamicin Followed by Blinatumomab for Ph-Negative CD22-Positive B-Lineage Acute Lymphoblastic Leukemia in Newly Diagnosed Older Adults or Adults With Relapsed or Refractory Disease
A Phase II Study of Inotuzumab Ozogamicin Followed by Blinatumomab for Ph-Negative CD22-Positive B-Lineage Acute Lymphoblastic Leukemia in Newly Diagnosed Older Adults or Adults With Relapsed or Refractory Disease
Enrollment Status: Suspended
Publish Date: September 22, 2025
Intervention Type: Biological
Study Drugs: Blinatumomab, Inotuzumab
Study Phase: Phase 2
A Phase 2 Study of Blinatumomab and POMP (Prednisone, Vincristine, Methotrexate, 6-Mercaptopurine) for Patients >/= 65 Years of Age With Newly Diagnosed Philadelphia-Chromosome Negative (Ph-) Acute Lymphoblastic Leukemia (ALL) and of Dasatinib, Prednisone and Blinatumomab for Patients >/= 65 Years of Age With Newly Diagnosed Philadelphia-Chromosome Positive (Ph+) ALL, Relapsed/Refractory Ph+ ALL, and Philadelphia-Chromosome-Like Signature (Ph-Like) ALL (Newly Diagnosed or Relapsed/Refractory) With Known or Presumed Activating Dasatinib-Sensitive Mutations or Kinase Fusions (DSMKF)
A Phase 2 Study of Blinatumomab and POMP (Prednisone, Vincristine, Methotrexate, 6-Mercaptopurine) for Patients >/= 65 Years of Age With Newly Diagnosed Philadelphia-Chromosome Negative (Ph-) Acute Lymphoblastic Leukemia (ALL) and of Dasatinib, Prednisone and Blinatumomab for Patients >/= 65 Years of Age With Newly Diagnosed Philadelphia-Chromosome Positive (Ph+) ALL, Relapsed/Refractory Ph+ ALL, and Philadelphia-Chromosome-Like Signature (Ph-Like) ALL (Newly Diagnosed or Relapsed/Refractory) With Known or Presumed Activating Dasatinib-Sensitive Mutations or Kinase Fusions (DSMKF)
Enrollment Status: Active_not_recruiting
Publish Date: September 15, 2025
Intervention Type: Procedure, Drug, Biological
Study Drugs: Blinatumomab, Dasatinib, Mercaptopurine, Methotrexate, Methotrexate Sodium, Prednisone, Vincristine, Vincristine Sulfate
Study Phase: Phase 2
A Phase 1b/2 Study of IMGN632 as Monotherapy or Combination With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia
A Phase 1b/2 Study of IMGN632 as Monotherapy or Combination With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia
Enrollment Status: Active_not_recruiting
Publish Date: August 14, 2025
Intervention Type: Drug
Study Drugs: Azacitidine, IMGN632, Venetoclax
Study Phase: Phase 1/Phase 2
A Phase II Multi-center, Single Arm, Safety and Efficacy Study of MBG453 in Combination With Azacitidine and Venetoclax for the Treatment of Acute Myeloid Leukemia (AML) in Adult Patients Unfit for Chemotherapy
A Phase II Multi-center, Single Arm, Safety and Efficacy Study of MBG453 in Combination With Azacitidine and Venetoclax for the Treatment of Acute Myeloid Leukemia (AML) in Adult Patients Unfit for Chemotherapy
Enrollment Status: Terminated
Publish Date: April 18, 2025
Intervention Type: Drug
Study Drugs: Sabatolimab, Venetoclax, Azacitidine
Study Phase: Phase 2
Phase II Trial of Vosaroxin in Combination With Infusional Cytarabine in Patients With Untreated AML
Phase II Trial of Vosaroxin in Combination With Infusional Cytarabine in Patients With Untreated AML
Enrollment Status: Completed
Publish Date: April 15, 2025
Intervention Type: Drug
Study Drugs: Cytarabine, Vosaroxin
Study Phase: Phase 2
A Phase 1b Trial of Magrolimab Monotherapy or Magrolimab in Combination With Azacitidine in Patients With Hematological Malignancies
A Phase 1b Trial of Magrolimab Monotherapy or Magrolimab in Combination With Azacitidine in Patients With Hematological Malignancies
Enrollment Status: Terminated
Publish Date: January 17, 2025
Intervention Type: Drug
Study Drugs: Magrolimab, Azacitidine
Study Phase: Phase 1
A Phase 1/2, Multi-center, Open-label Study of IMGN632 Monotherapy Administered Intravenously in Patients With CD123-positive Acute Myeloid Leukemia and Other CD123-positive Hematologic Malignancies
A Phase 1/2, Multi-center, Open-label Study of IMGN632 Monotherapy Administered Intravenously in Patients With CD123-positive Acute Myeloid Leukemia and Other CD123-positive Hematologic Malignancies
Enrollment Status: Active_not_recruiting
Publish Date: December 16, 2024
Intervention Type: Drug
Study Drug: IMGN-632 CD123-Targeting Antibody-Drug Conjugate
Study Phase: Phase 1/Phase 2
A Phase III Randomized, Double-Blind Trial to Evaluate the Efficacy of Uproleselan Administered With Chemotherapy Versus Chemotherapy Alone in Patients With Relapsed/Refractory Acute Myeloid Leukemia
A Phase III Randomized, Double-Blind Trial to Evaluate the Efficacy of Uproleselan Administered With Chemotherapy Versus Chemotherapy Alone in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Enrollment Status: Terminated
Publish Date: July 29, 2024
Intervention Type: Drug
Study Drug: Uproleselan
Study Phase: Phase 3
A Randomized Phase II Study of Ruxolitinib (NSC-752295) in Combination With BCR-ABL Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia (CML) Patients With Molecular Evidence of Disease
A Randomized Phase II Study of Ruxolitinib (NSC-752295) in Combination With BCR-ABL Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia (CML) Patients With Molecular Evidence of Disease
Enrollment Status: Active_not_recruiting
Publish Date: July 08, 2024
Intervention Type: Drug, Other
Study Drugs: Bosutinib, Dasatinib, Nilotinib, Nilotinib Hydrochloride Monohydrate, Ruxolitinib, Ruxolitinib Phosphate
Study Phase: Phase 2
A Phase 1/2, First in Human, Dose Escalation Study of MGD006, a CD123 x CD3 DART® Bi-Specific Antibody Based Molecule, in Patients With Relapsed or Refractory AML or Intermediate-2/High Risk Myelodysplastic Syndrome (MDS)
A Phase 1/2, First in Human, Dose Escalation Study of MGD006, a CD123 x CD3 DART® Bi-Specific Antibody Based Molecule, in Patients With Relapsed or Refractory AML or Intermediate-2/High Risk Myelodysplastic Syndrome (MDS)
Enrollment Status: Terminated
Publish Date: January 30, 2024
Intervention Type: Biological, Drug
Study Drug: Flotetuzumab
Study Phase: Phase 1/Phase 2
S0919, A Phase II Study of Idarubicin and Ara-C in Combination With Pravastatin for Poor-Risk Acute Myelogenous Leukemia
S0919, A Phase II Study of Idarubicin and Ara-C in Combination With Pravastatin for Poor-Risk Acute Myelogenous Leukemia
Enrollment Status: Completed
Publish Date: May 03, 2023
Intervention Type: Drug
Study Drugs: Cytarabine, Idarubicin, Pravastatin
Study Phase: Phase 2
Phase 1B Study of PTC299 in Relapsed/Refractory Acute Leukemias
Phase 1B Study of PTC299 in Relapsed/Refractory Acute Leukemias
Enrollment Status: Terminated
Publish Date: February 02, 2022
Intervention Type: Drug
Study Drug: PTC299
Study Phase: Phase 1
A Phase 1 Study of SGN-CD123A in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)
A Phase 1 Study of SGN-CD123A in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)
Enrollment Status: Terminated
Publish Date: May 14, 2018
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1b Dose-escalation Study of SGN-CD33A in Combination With Standard-of-care for Patients With Newly Diagnosed Acute Myeloid Leukemia
A Phase 1b Dose-escalation Study of SGN-CD33A in Combination With Standard-of-care for Patients With Newly Diagnosed Acute Myeloid Leukemia
Enrollment Status: Completed
Publish Date: May 09, 2018
Intervention Type: Drug
Study Phase: Phase 1
View 16 Less Clinical Trials

137 Total Publications

Ziftomenib in Relapsed or Refractory NPM1-Mutated AML.
Ziftomenib in Relapsed or Refractory NPM1-Mutated AML.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: September 25, 2025
Similar Doctors
Expertise in
15
conditions
Dr. Sascha A. Tuchman
Hematology | Oncology | Transplant Surgery
Expertise in
15
conditions
Dr. Sascha A. Tuchman
Hematology | Oncology | Transplant Surgery

University Of North Carolina At Chapel Hill

101 Manning Dr, 
Chapel Hill, NC 
 (9.6 miles away)
984-974-1000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Sascha Tuchman is a Hematologist and an Oncologist in Chapel Hill, North Carolina. Dr. Tuchman is highly rated in 15 conditions, according to our data. His top areas of expertise are Multiple Myeloma, Relapsed Refractory Multiple Myeloma (RRMM), Monoclonal Gammopathy of Undetermined Significance (MGUS), Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Tuchman is currently accepting new patients.

Expertise in
16
conditions
Dr. Matthew I. Milowsky
Oncology | Hematology
Expertise in
16
conditions
Dr. Matthew I. Milowsky
Oncology | Hematology

University Of North Carolina At Chapel Hill

101 Manning Dr, 
Chapel Hill, NC 
 (9.6 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Matthew Milowsky is an Oncologist and a Hematologist in Chapel Hill, North Carolina. Dr. Milowsky is highly rated in 16 conditions, according to our data. His top areas of expertise are Urothelial Cancer, Bladder Cancer, Muscle Invasive Bladder Cancer, Orchiectomy, and Tissue Biopsy. Dr. Milowsky is currently accepting new patients.

Expertise in
15
conditions
Dr. April K. Salama
Hematology | Oncology
Expertise in
15
conditions
Dr. April K. Salama
Hematology | Oncology

Duke Cancer Center

20 Duke Medicine Cir, 
Durham, NC 
 (0.2 miles away)
919-681-6900
Experience:
21+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

I am a medical oncologist who specializes in the treatment of patients with skin cancer. I am part of a team of surgical oncologists, dermatologists, and radiation oncologists who all work together to determine the best treatment approach for each patient. My focus is on treating patients with advanced melanoma, as well as melanoma that is at high risk for recurrence after surgery. We also treat patients with merkel cell carcinoma and advanced basal cell and cutaneous squamous cell carcinoma. We also have a number of clinical trial options available, allowing our patients access to the newest therapies available. Dr. Salama is highly rated in 15 conditions, according to our data. Her top areas of expertise are Melanoma, Melanoma of the Eye, Metastatic Uveal Melanoma, and Primitive Neuroectodermal Tumor (PNET).

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Erba's expertise for a condition
ConditionClose
View All 7 Distinguished Conditions
View All 13 Advanced Conditions
View All 32 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile